RPG Life Sciences Q2 FY27 Revenue Surges 16.5% to ₹211.6 Cr
RPG Life Sciences announced its financial results for the quarter and half-year ended September 30, 2026. Revenue from Operations grew by 16.5% to ₹211.6 crore in Q2 FY27, crossing the ₹200 crore milestone. Gross margin expanded by 260 basis points. Adjusted EBITDA (excluding one-off costs) grew 15% to ₹50.1 crore, representing 23.7% of revenue. The Domestic Formulations business showed strong growth, ranking as the 4th fastest-growing company in IPM, with its flagship brand Naprosyn crossing ₹100 crore in sales. The company also made significant strides in its API business by transferring it to RPG Active Pharma and acquiring two API plants, expanding manufacturing capacity fivefold. The acquired sites are expected to contribute fully from Q3 onwards.
Key Highlights
- Q2 FY27 revenue grew 16.5% to ₹211.6 crore, surpassing ₹200 crore.
- Adjusted EBITDA increased 15% to ₹50.1 crore, maintaining a healthy 23.7% margin.
- Domestic Formulations business is the 4th fastest growing in IPM.
- Flagship brand Naprosyn achieved ₹100 crore in sales.
- API business significantly expanded with new acquisitions and investor onboarding.
Price Impact
More from RPGLIFE